Other languages Foghorn Therapeutics Inc.

Equities

FHTX

US3441741077

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-02 EDT			5-day change	1st Jan Change
6.11 ^USD	+4.27%		+16.83%	-5.27%

04-16	Foghorn Therapeutics Names Kristian Humer CFO	MT
04-16	Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07
Foghorn Therapeutics Inc. to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909	03-05
Eli Lilly : un antitumoral de Foghorn a été sélectionné	02-08
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor	02-08
Foghorn Therapeutics Inc. Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024	01-08
Prime Medicine Names Foghorn Therapeutics' CFO to be its New Finance Chief	01-05
Foghorn Therapeutics Says CFO is Leaving; Shares Fall After-Hours	01-03
Foghorn Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02
Foghorn Therapeutics Inc. to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference	23-10-04
Foghorn Therapeutics Begins Phase 1 Combination Study of FHD-286 to Treat AML	23-08-31
Foghorn Therapeutics Inc. Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed And/Or Refractory AML	23-08-31
Insider Sell: Foghorn Therapeutics	23-08-18
Foghorn Therapeutics Inc Announces Executive Changes	23-08-08
Foghorn Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04
Pfizer y Flagship Pioneering invertirán 100 millones de dólares en el descubrimiento de fármacos	23-07-18
Pfizer, Flagship Pioneering to invest $100 mln for drug discovery	23-07-18
Foghorn Therapeutics Halts Advance of FHD-286 to Treat Rare Eye Cancer; Shares Drop Pre-Bell	23-06-28
FOGHORN THERAPEUTICS SHARES HIT 4-MONTH HIGH AFTER FDA LIFTS CLI…	23-06-05
Foghorn Therapeutics Says FDA Lifts Clinical Hold on Dose Escalation Study of FHD-286	23-06-05
Foghorn Therapeutics Announces FDA Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients	23-06-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Foghorn Therapeutics Inc.

Equities

FHTX

US3441741077

Other languages

Filters